SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?


To: Sergio H who wrote (773)2/17/1998 10:49:00 PM
From: ilh1  Respond to of 29382
 
"Founded in 1992, Isonics Corporation ("Isonics" or the "Company") is a specialty chemical and advanced materials company which develops and
commercializes products based on stable isotopes. Stable isotopes are
ultra-ultra pure materials engineered at the molecular level to provide enhanced performance properties in semiconductors, lasers, high performance lighting, and energy production. Stable isotopes are also widely used in basic research, pharmaceutical development and drug design, as well as in medical diagnostics and imaging.

By replacing materials traditionally used in these industries with
isotopically engineered versions of the same materials, product
performance, safety, and economics can be enhanced significantly.
Using state-of-the-art technology, Isonics produces a wide range of enriched stable isotopes which are then converted into products which meet the specialized needs of Isonics'customers.

Isonics' core business is production and supply of depleted zinc (DZ), a non-radioactive stable isotope, to the energy industry. In fiscal 1996, Isonics expanded its business scope to include development of isotopically engineered materials for the medical research, medical diagnostic, and semiconductor industries.

In June 1997 Isonics produced the world's first isotopically pure silicon epitaxial wafer suitable for semiconductor fabrication.

In July 1997 Isonics exercised an option for an exclusive license for two U.S. patents owned by Yale University concerning isotopically pure silicon and a wide range of other semiconductor materials. The Company is currently evaluating potential applications for isotopically pure silicon in collaboration with certain industrial and university partners and is developing strategies for commercialization.

Isonics is supplying stable isotope labeled compounds ("SILCs"), mainly enriched carbon for pharmaceutical research and medical
diagnostic test development. The Company is developing advanced, lower
cost, production technology for enriched carbon which the Company believes will allow it to become the cost leader in the potentially large enriched carbon market supporting a new class of minimally invasive diagnostic tests which are being developed by others.

The Company believes that a substantial portion of its revenues in the future will depend on its success in developing and selling products in the semiconductor and SILC markets."

-Prosperous Soul-



To: Sergio H who wrote (773)2/17/1998 10:57:00 PM
From: ilh1  Read Replies (1) | Respond to of 29382
 
This ISON press release further reveals the great promise of ISON:

Wednesday January 21, 7:30 am Eastern Time

Company Press Release



SOURCE: Isonics Corporation

Isonics Corporation Announces New Isotopically
Pure Silicon-28 Epitaxial Wafer

SAN JOSE, Calif., Jan. 21 /PRNewswire/ -- Isonics Corporation (OTC : ISON - news)
announced the introduction of an advanced silicon wafer with improved thermal conductivity for the semiconductor industry.

The Company believes that the improved thermal characteristics of these wafers, composed of a single isotope of silicon, Silicon-28, will facilitate the manufacture of higher density integrated circuits resulting in increased performance, improved chip yields, and shorter time-to-market for new designs. The elegance of isotopically pure
Silicon-28 is that while it has better thermal properties than standard silicon, it can be used without any changes in existing silicon semiconductor manufacturing processes.
At present the Company is identifying potential development partners to aid in evaluating this advanced material in a spectrum of applications.

Isonics President and CEO, James E. Alexander stated, ''While Silicon-28 has been shown superior in certain thermal conductivity tests, we have not yet identified the full range and magnitude of benefits that isotopically pure Silicon-28 may ultimately
provide the semiconductor industry. We anticipate that the benefits will be very application specific. Semiconductors today are so complex that the benefits of our Silicon-28 cannot be analyzed in advance. Instead, they must be proven by manufacturing existing products using our new Silicon-28 wafers and then comparing the results to standard wafers.

''We believe there are substantial benefits for current applications, but we also expect that the properties of our improved silicon will become critically important as the industry transitions to 12-inch wafers, copper interconnects and 0.18 micron design rules.''

Tests have shown that isotopically pure Silicon-28 has greater than 50 percent better thermal conductivity than natural silicon. The manufacture of these ultra-pure wafers involves growing an isotopically pure Silicon-28 epitaxial layer on a standard silicon
single-crystal wafer. Silicon-28 epitaxial wafers are currently available in 4, 5, 6 and 8-inch diameters with n-type or p-type doping to customer specifications in quantities sufficient for prototype runs.

Isonics is an advanced materials and technology company which develops and commercializes products based on enriched stable isotopes. Stable isotopes can be thought of as ultra-ultra pure materials. This high degree of purification provides enhanced performance properties compared to normal materials. Stable isotopes have commercial uses in several areas, including energy; research, medical diagnostics, and drug development; product tagging and stewardship; semiconductors; lasers; and optical materials.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's Prospectus, dated September 23, 1997 and the Company's 1O-QSB dated October 31, 1997, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained in these filings, readers are urged to carefully read all cautionary statements contained in these filings
with the Securities and Exchange Commission.

-Prosperous Soul-



To: Sergio H who wrote (773)2/17/1998 11:23:00 PM
From: ilh1  Read Replies (1) | Respond to of 29382
 
ISON PRINCIPAL SHAREHOLDERS

The following table sets forth certain information known to the Company regarding beneficial ownership of the Common Stock as of July 31, 1997, and as adjusted to reflect the sale of the Securities offered hereby, by (i) each person known by the Company to be the beneficial owner of more than 5% of the Common Stock, (ii) each of the Company's directors, (iii) each Named Person and (iv) all executive officers and directors as a group. The address of each person is in care of the Company,

4010 Moorpark Avenue
Suite 119, San Jose, CA
95117.

<TABLE>
<CAPTION>
SHARES BENEFICIALLY SHARES BENEFICIALLY
OWNED PRIOR TO OWNED AFTER
OFFERING(1) OFFERING(1)(2)
----------------------------------------------
DIRECTORS, NAMED PERSONS, AND 5%
SHAREHOLDERS NUMBER PERCENT NUMBER PERCENT
-------------------------------- ------------ --------- ------------- ----------
<S> <C> <C> <C> <C>
James E. Alexander(3)(10).......... 2,155,764 shares (46.4%) 2,155,764 39.6
Boris Rubizhevsky(3)(8)(9)......... 1,919,201 shares (41.4%) 1,919,201 35.3
Jacques Delente(4)................. 355,401 shares (7.6%) 355,401 6.5
Lindsay Gardner(5)................. 263,785 shares (5.7%) 263,785 4.8
Larry Wells(6)..................... 171,857 shares (3.6%) 171,857 3.1
Daniel J. Grady(11)................ 207,340 shares (4.4%) 207,340 3.7
All executive officers and
directors as a group (7
persons)(7)....................... 4,994,399 shares (91.2%) 4,994,399 79.5
</TABLE>
- --------
(1) The persons named in the table have sole voting and sole investment power with respect to all shares beneficially owned, subject to community property laws where applicable.
(2) Assumes that the Underwriters' over-allotment option to purchase up to 120,000 Shares and 120,000 Warrants included in 120,000 Units from the Company is not exercised. See "Underwriting."
(3) Includes 164,144 shares of Common Stock subject to a repurchase right in favor of the Company.
(4) Includes 217,707 shares of Common Stock subject to a repurchase right in favor of the Company, and warrants to purchase 122,854 shares of Common Stock issued in connection with the Placement.
(5) Includes warrants to purchase 91,003 shares of Common Stock issued in connection with the Placement.
(6) Includes 171,857 shares issuable upon the exercise of Placement Warrants held by an entity with which Mr. Wells is affiliated.
(7) Includes 328,288 shares of Common Stock subject to a repurchase right in favor of the Company, options to purchase 483,794 shares of Common Stock, and warrants to purchase 444,865 shares of Common Stock issued in connection with the Placement and 91,729 shares of Common Stock held by Mr. Rubizhevsky's wife.
(8) Includes 91,729 shares of Common Stock held by Mr. Rubizhevsky's wife.
(9) Includes 91,002 shares issuable upon the exercise of Placement
Warrants held by the mother, father, mother-in-law and father-in-law of Mr. Rubizhevsky.
(10) Includes 91,002 shares issuable upon the exercise of Placement Warrants held by the brother-in-law, mother-in-law and father-in-law of Mr. Alexander.
(11) Includes 207,340 shares issuable upon the exercise of fully exercisable stock options.

ISON has 5.3Mil shares outstanding, 800,000 share FLOAT.

-Prosperous Soul-